Lantern Pharma is trading 5.2% down today at $2.94 after hitting a new 52-week low of $2.77, extending a steep decline from its prior high of $8.27.
- Recent market analysis flags the stock as volatile and oversold following the sustained downward trend.
- The price action occurs amid broader sector-wide challenges currently impacting biotech and pharmaceutical companies.